Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Sponsor
Fan Yun, MD
Study ID
NCT02945852
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • apatinib — DRUG
    apatinib 500mg/d until progressive Disease

Study Details

Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and etoposide(CE)and second-line therapy with topotecan has been given, patients with extensive small cell lung cancer(ED-SCLC) still relapse and 2-year survival is less than 10%. There is no standard treatment recommendation for this group of patients who failed to second-line therapy and had good performance status. Apatinib has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in small cell lung cancer is still lack of evidence-based medicine. And this clinical trial is designed to prospectively investigate the efficacy and safety of apatinib in refractory or recurrent ED-SCLC patients in our center.

Key Dates

Start date
Oct 31, 2016
Status verified
Jul 2022
Primary completion
Nov 15, 2018
Completion
May 26, 2019

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: refractory SCLC
    Patients receive apatinib 500mg/d until progressive Disease(PD).

Primary Outcome Measure

Progression-free survival [ Time Frame: 3 months ]

Related Studies